Journal List > Korean J Obstet Gynecol > v.53(5) > 1006410

TOOLS
Song, Park, Hwang, Im, Lee, and Lee: Clinical data of patients with endometrioid endometrial adenocarcinoma at a single institution
Original Article
Korean Journal of Obstetrics and Gynecology

Korean Journal of Obstetrics and Gynecology 2010; 53(5): 396-400.

Published online: 31 May 2010

DOI: https://doi.org/10.5468/kjog.2010.53.5.396

Clinical data of patients with endometrioid endometrial adenocarcinoma at a single institution

Eunseop Song, M.D.1, 2, Jee-Hyun Park, M.D.1, Sung-Ook Hwang, M.D.1, Moon-Whan Im, M.D.1, Byoung-Ick Lee, M.D.1, Woo-Young Lee, M.D.1

1Department of Obstetrics and Gynecology, Inha University, Incheon, Korea.

2Inha Research Institute for Medical Science, Inha University, Incheon, Korea.

Corresponding author (songsong2000@hotmail.com)

Received 8 February 2010       Accepted 8 April 2010

Copyright © 2010 Korean Society of Obstetrics and Gynecology

Abstract

Objective

The incidence of endometrial cancer is increasing. We would like to report our institution's clinical data of endometrioid adenocarcinoma (EC) which is the most frequent type.

Methods

From 1998 to 2009, patients' clinical data were reviewed through medical records, retrospectively.

Results

For 11 years, there were 96 patients with EC. The average age was 51.1 years old and mean follow duration was 36.6 months. There were 73 patients with stage I, 10 patients with stage II, and 12 patients with stage III. 42 patients were treated by operation only and 46 patients were treated by operation and adjuvant radiotherapy. Among 95 patients who underwent operations, 32 patients did not get lymph node removal and 63 did, and 10 patients had malignant cells at the lymph nodes removed. 6 patients died of EC, 1 with stage I, 3 with stage II and 1 with stage III.

Conclusion

This study had retrospective limitation but could show the profile of 96 patients with EC.

Keywords: Carcinoma, Endometrioid

Figures and Tables

Table 1
Clinical profile of the patients
kjog-53-396-i001

FIGO: The International Federation of Gynecology and Obstetrics, SO: simple hysterectomy with both salpingo-oophorectomy with/without lymph node sampling/dissection, RO: radical hysterectomy with both salpingo-oophorectomy with/without lymph node sampling/dissection, RT: radiotherapy, CCRT: concurrent chemoradiation, NA: not available.

Table 2
The results of lymph node removal at the operation
kjog-53-396-i002

FIGO: The International Federation of Gynecology and Obstetrics, LN/0: no removal of lymph node, LNR: removal of lymph nodes, LN (+): number of lymph node found malignant.

Table 3
Patient profile of expired patients
kjog-53-396-i003

FIGO: The International Federation of Gynecology and Obstetrics, LNN: number of removed lymph node, LN (+): number of lymph node found malignant, SO: simple hysterectomy with both salpingo-oophorectomy with/without lymph node sampling/dissection, RO: radical hysterectomy with both salpingo-oophorectomy with/without lymph node sampling/dissection, RT: radiotherapy, NA: not available.

References

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007. 57:43–66.
2. Annual Report of cancer incidence (2007), cancer prevalence (2007) and survival (1993-2007) in Korea. Ministry for Health, Welfare and Family Affairs. 2009. Seoul: Ministry for Health Welfare and Family Affairs;Available from: http://www.cancer.or.kr/.
3. Sabatino SA, Stewart SL, Wilson RJ. Racial and ethnic variations in the incidence of cancers of the uterine corpus, United States, 2001-2003. J Womens Health (Larchmt). 2009. 18:285–294.
4. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005. 55:74–108.
5. Song SH, Lee JK, Oh MJ, Hur JY, Park YK, Saw HS. Clinicopathologic characteristics and prognostic factors of stage I and II endometrial cancer of the uterus: A study of 59 Cases. Korean J Obstet Gynecol. 2006. 49:1267–1275.
6. Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, et al. Carcinoma of the corpus uteri. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006. 95:Suppl 1. S105–S143.
7. Lee HP. Annual report of gynecologic cancer registry program in Korea: 1991~2004. Korean J Obstet Gynecol. 2008. 51:1411–1420.
8. Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009. 373:125–136.
9. Dowdy SC, Mariani A. Lymphadenectomy in endometrial cancer: when, not if. Lancet. 2010. 375:1138–1140.
10. Abeler VM, Kjorstad KE. Endometrial adenocarcinoma in Norway. A study of a total population. Cancer. 1991. 67:3093–3103.
11. Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1991. 40:55–65.
12. Grigsby PW, Perez CA, Kuten A, Simpson JR, Garcia DM, Camel HM, et al. Clinical stage I endometrial cancer: prognostic factors for local control and distant metastasis and implications of the new FIGO surgical staging system. Int J Radiat Oncol Biol Phys. 1992. 22:905–911.
13. Alvarez Secord A, Havrilesky LJ, Bae-Jump V, Chin J, Calingaert B, Bland A, et al. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer. Gynecol Oncol. 2007. 107:285–291.
14. Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004. 92:744–751.
15. Thigpen JT, Brady MF, Homesley HD, Malfetano J, DuBeshter B, Burger RA, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol. 2004. 22:3902–3908.
16. O'Brien ME, Killackej M. Adjuvant therapy in high-risk endometrial adenocarcinoma. Proc Ann Meet Soc Clin Oncol. 1994. 13:240.
TOOLS
Similar articles